Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
106,173,637
-
Shares change
-
+5,674,785
-
Total reported value, excl. options
-
$402,396,029
-
Value change
-
+$22,237,368
-
Put/Call ratio
-
177%
-
Number of buys
-
65
-
Number of sells
-
-55
-
Price
-
$3.79
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2021
158 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 106,173,637 shares
of 236,234,693 outstanding shares and own 44.94% of the company stock.
Largest 10 shareholders include STATE STREET CORP (14,006,637 shares), BlackRock Inc. (13,174,681 shares), VANGUARD GROUP INC (12,155,719 shares), WELLINGTON MANAGEMENT GROUP LLP (10,736,859 shares), Nantahala Capital Management, LLC (5,170,063 shares), JPMORGAN CHASE & CO (4,947,590 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), MARSHALL WACE, LLP (4,109,589 shares), DIMENSIONAL FUND ADVISORS LP (3,405,121 shares), and GOLDMAN SACHS GROUP INC (3,107,536 shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.